Lawsuit filed for Investors who lost money with shares of Indivior PLC (NASDAQ: INDV)

An investor, who purchased shares of Indivior PLC (NASDAQ: INDV), filed a lawsuit over alleged violations of Federal Securities Laws by Indivior PLC in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Indivior PLC (NASDAQ: INDV) have certain options and for certain investors are short and strict deadlines running. Deadline: October 1, 2024. NASDAQ: INDV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

North Chesterfield, VA based Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.

Indivior PLC reported that its annual Total Revenue rose from $901 million in 2022 to over $1.09 billion in 2023, and that its Net Loss of $53 million in 2022 turned to a Net Income of $2 million in 2023.

On July 9, 2024, Indivior PLC disclosed that it would be immediately ceasing all sales and marketing activities related to its schizophrenia treatment, PERSERIS due to the highly competitive market "and impending changes that are expected to intensify payor management in the treatment category in which PERSERIS participates." Additionally, the Company significantly reduced its 2024 net revenue guidance.

Shares of Indivior PLC (NASDAQ: INDV) declined from $23.89 per share on August 29, 2023, to as low as $9.14 per share on July 09, 2024.

The plaintiff claims that between February 22, 2024 and July 8, 2024, the Defendants grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than Defendants had led investors and analysts to believe, that the defendants overstated the financial prospects of SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company's anticipated revenue and other financial metrics, that the defendants knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior's products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY 2024 net revenue guidance, including its FY 2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE, that the defendants knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS, and that as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Indivior PLC (NASDAQ: INDV) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.